Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by LSV Asset Management

LSV Asset Management cut its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 19.2% during the 4th quarter, HoldingsChannel reports. The fund owned 4,081,501 shares of the biotechnology company’s stock after selling 970,100 shares during the period. LSV Asset Management’s holdings in Ironwood Pharmaceuticals were worth $18,081,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $68,000. Renaissance Technologies LLC increased its holdings in shares of Ironwood Pharmaceuticals by 5.5% in the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock valued at $40,163,000 after acquiring an additional 469,043 shares during the last quarter. Bank of Montreal Can raised its position in shares of Ironwood Pharmaceuticals by 81.1% during the 4th quarter. Bank of Montreal Can now owns 24,758 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 11,089 shares in the last quarter. Federated Hermes Inc. bought a new position in Ironwood Pharmaceuticals during the fourth quarter worth $1,641,000. Finally, Envestnet Asset Management Inc. acquired a new position in Ironwood Pharmaceuticals in the fourth quarter worth $50,000.

Insider Transactions at Ironwood Pharmaceuticals

In related news, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 192,381 shares of company stock valued at $338,591. 12.90% of the stock is currently owned by corporate insiders.

Ironwood Pharmaceuticals Stock Down 6.4 %

Ironwood Pharmaceuticals stock opened at $0.95 on Friday. Ironwood Pharmaceuticals, Inc. has a 52-week low of $0.91 and a 52-week high of $8.45. The firm has a market capitalization of $152.99 million, a price-to-earnings ratio of -31.52 and a beta of 0.30. The firm has a 50-day moving average price of $1.55 and a two-hundred day moving average price of $3.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. JMP Securities dropped their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 29th. Finally, Craig Hallum decreased their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.60.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.